Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer

• 收藏
• 分享

专利权人:

AstraZeneca AB

发明人:

BOIKO, Scott,CIDADO, Justin,DREW, Lisa,PROIA, Theresa,SAN MARTIN, Maryann

申请号：

AU2018335617

公开号：

AU2018335617A1

申请日:

2018.09.24

申请国别(地区):

AU

年份:

2020

代理人:

摘要：

The present invention relates to combination of a BTK inhibitor and an inhibitor of CDK9 for use in the treatment of cancer in a subject. The BTK inhibitor can be acalabrutinib, ibrutinib, or ONO/GS-4059； and the inhibitor of CDK9 can be AZD4573, BAY-1251152, BAY- 1143572, CYC065, alvocidib, AT7519, voruciclib, roniciclib, or dinaciclib.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/